CRBP Stock News & Catalysts – Corbus Pharmaceuticals

FEATURED

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November

NORWOOD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive

Summary

Nov 5, 2026, 8:00 AM ·Globe Newswire

RECENT

Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026

NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data

Oct 22, 2026, 8:00 AM ·Globe Newswire

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately

Sep 29, 2026, 8:00 AM ·Globe Newswire

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observedCRB-913 was generally well tolerated with psychiatric adverse events

Sep 14, 2026, 7:00 AM ·Globe Newswire

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

NORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the

Sep 11, 2026, 4:01 PM ·Globe Newswire

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the grant of inducement

Aug 17, 2026, 10:00 AM ·Globe Newswire

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026Concluded last patient last visit in CANYON-1 Phase 1b study

Aug 6, 2026, 8:00 AM ·Globe Newswire

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Dose-finding Phase 1b study (n=240) on track for topline data in September 2026CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 classCRB-913 yielded

Aug 4, 2026, 8:30 AM ·Globe Newswire

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Company expects to initiate enrollment in TEMPO-1 in September 2026OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually

Jul 28, 2026, 8:00 AM ·Globe Newswire

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage company focused on developing promising new therapies

Jul 6, 2026, 8:00 AM ·Globe Newswire

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forward Confirmed ORR of 42.9% observed in 2L

May 26, 2026, 7:00 AM ·Globe Newswire

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that

May 21, 2026, 8:00 AM ·Globe Newswire

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the

May 14, 2026, 8:00 AM ·Globe Newswire

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that

May 13, 2026, 7:00 AM ·Globe Newswire

Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701Announced presentation of updated CRB-701 data

May 12, 2026, 8:00 AM ·Globe Newswire

Corbus Pharmaceuticals Holdings, Inc. CRBP · News